Cloning and production of human von Willebrand Factor GP1b binding domain polypeptides and methods of using same

The subject invention provides non-glycosylated, biologically active polypeptides which comprise the vWF (van Willebrand Factor) GP1b binding domain. These polypeptides may be used to inhibit platelet adhesion and aggregation in the treatment of subjects with conditions such as cerebrovascular disorders and cardiovascular disorders. This invention also provides expression plasmids encoding these polypeptides as well as methods of producing by transforming a bacterial cell and recovering such polypeptides. In addition, the subject invention provides methods of treating and preventing cerebrovascular, cardiovascular and other disorders using these polypeptides to inhibit platelet aggregation.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. An expression plasmid encoding a polypeptide having the amino acid sequence X-A-Cys Ser Arg Leu Leu Asp Leu Val Phe Leu Leu Asp Gly Ser Ser Arg Leu Ser Glu Ala Glu Phe Glu Val Leu Lys Ala Phe Val Val Asp Met Met Glu Arg Leu Arg Ile Ser Gln Lys Trp Val Arg Val Ala Val Val Glu Tyr His Asp Gly Ser His Ala Tyr Ile Gly Leu Lys Asp Arg Lys Arg Pro Ser Glu Leu Arg Arg Ile Ala Ser Gln Val Lys Tyr Ala Gly Ser Gln Val Ala Ser Thr Ser Glu Val Leu Lys Tyr Thr Leu Phe Gln Ile Phe Ser Lys Ile Asp Arg Pro Glu Ala Ser Arg Ile Ala Leu Leu Leu Met Ala Ser Gln Glu Pro Gln Arg Met Ser Arg Asn Phe Val Arg Tyr Val Gln Gly Leu Lys Lys Lys Lys Val Ile Val Ile Pro Val Gly Ile Gly Pro His Ala Asn Leu Lys Gln Ile Arg Leu Ile Glu Lys Gln Ala Pro Glu Asn Lys Ala Phe Val Leu Ser Ser Val Asp Glu Leu Glu Gln Gln Arg Asp Glu Ile Val Ser Tyr Leu Cys Asp Leu Ala Pro Glu Ala Pro Pro Pro Thr Leu Pro Pro Asp Met Ala Gln Val Thr Val Gly Pro Gly Leu Leu Gly Val Ser Thr Leu Gly Pro Lys-COOH

A is a sequence of at least 1, but no more than 5 amino acids, which sequence is present in naturally-occurring human vWF, the carboxy terminal amino acid of which is the tyrosine #508 shown in FIG. 12 and each succeeding amino acid of which is the next successive N-terminal amino acid shown in FIG. 12; and
the two cysteines included in the sequence are joined by a disulfide bond.

2. An expression plasmid designated pvWF-VC3 and deposited under ATCC Accession No. 68241 encoding a polypeptide having the amino acid sequence X-Leu His Asp Phe Tyr Cys Ser Arg Leu Leu Asp Leu Val Phe Leu Leu Asp Gly Ser Ser Arg Leu Ser Glu Ala Glu Phe Glu Val Leu Lys Ala Phe Val Val Asp Met Met Glu Arg Leu Arg Ile Ser Gln Lys Trp Val Arg Val Ala Val Val Glu Tyr His Asp Gly Ser His Ala Tyr Ile Gly Leu Lys Asp Arg Lys Arg Pro Ser Glu Leu Arg Arg Ile Ala Ser Gln Val Lys Tyr Ala Gly Ser Gln Val Ala Ser Thr Ser Glu Val Leu Lys Tyr Thr Leu Phe Gln Ile Phe Ser Lys Ile Asp Arg Pro Glu Ala Ser Arg Ile Ala Leu Leu Leu Met Ala Ser Gln Glu Pro Gln Arg Met Ser Arg Asn Phe Val Arg Tyr Val Gln Gly Leu Lys Lys Lys Lys Val Ile Val Ile Pro Val Gly Ile Gly Pro His Ala Asn Leu Lys Gln Ile Arg Leu Ile Glu Lys Gln Ala Pro Glu Asn Lys Ala Phe Val Leu Ser Ser Val Asp Glu Leu Glu Gln Gln Arg Asp Glu Ile Val Ser Tyr Leu Cys Asp Leu Ala Pro Glu Ala Pro Pro Pro Thr Leu Pro Pro Asp Met Ala Gln Val Thr Val Gly Pro Gly Leu Leu Gly Val Ser Thr Leu Gly Pro Lys-COOH

and the two cysteines included in the sequence are joined by a disulfide bond.

3. An expression plasmid designated pvWF-VCL deposited under ATCC Accession No. 68242 encoding a polypeptide having the amino acid sequence X-Leu His Asp Phe Tyr Cys Ser Arg Leu Leu Asp Leu Val Phe Leu Leu Asp Gly Ser Ser Arg Leu Ser Glu Ala Glu Phe Glu Val Leu Lys Ala Phe Val Val Asp Met Met Glu Arg Leu Arg Ile Ser Gln Lys Trp Val Arg Val Ala Val Val Glu Tyr His Asp Gly Ser His Ala Tyr Ile Gly Leu Lys Asp Arg Lys Arg Pro Ser Glu Leu Arg Arg Ile Ala Ser Gln Val Lys Tyr Ala Gly Ser Gln Val Ala Ser Thr Ser Glu Val Leu Lys Tyr Thr Leu Phe Gln Ile Phe Ser Lys Ile Asp Arg Pro Glu Ala Ser Arg Ile Ala Leu Leu Leu Met Ala Ser Gln Glu Pro Gln Arg Met Ser Arg Asn Phe Val Arg Tyr Val Gln Gly Leu Lys Lys Lys Lys Val Ile Val Ile Pro Val Gly Ile Gly Pro His Ala Asn Leu Lys Gln Ile Arg Leu Ile Glu Lys Gln Ala Pro Glu Asn Lys Ala Phe Val Leu Ser Ser Val Asp Glu Leu Glu Gln Gln Arg Asp Glu Ile Val Ser Tyr Leu Cys Asp Leu Ala Pro Glu Ala Pro Pro Pro Thr Leu Pro Pro Asp Met Ala Gln Val Thr Val Gly Pro Gly Leu Leu Gly Val Ser Thr Leu Gly Pro Lys-COOH

and the two cysteines included in the sequence are joined by a disulfide bond.

4. A method of producing a biologically active composition comprising a polypeptide which comprises transforming a cell with the expression plasmid of claim 1 encoding the polypeptide, culturing the resulting cell so that the cell produces the polypeptide encoded by the plasmid, and recovering the polypeptide so produced.

5. A method of producing a biologically active composition comprising a polypeptide which comprises transforming a cell with the expression plasmid of claim 2 encoding the polypeptide, culturing the resulting cell so that the cell produces the polypeptide encoded by the plasmid, and recovering the polypeptide so produced.

6. A method of producing a biologically active composition comprising a polypeptide which comprises transforming a cell with the expression plasmid of claim 3 encoding the polypeptide, culturing the resulting cell so that the cell produces the polypeptide encoded by the plasmid, and recovering the polypeptide so produced.

Referenced Cited
U.S. Patent Documents
4620948 November 4, 1986 Builder et al.
4666884 May 19, 1987 Hawiger et al.
5200510 April 6, 1993 Kumar et al.
5238919 August 24, 1993 Zimmerman et al.
5321127 June 14, 1994 Handin
5340727 August 23, 1994 Ruggeri et al.
5344783 September 6, 1994 Scarborough et al.
Foreign Patent Documents
0160457 April 1985 EPX
169562 January 1986 EPX
8606096 October 1986 EPX
197592 October 1986 EPX
8606745 November 1986 EPX
255206 February 1988 EPX
0255206 February 1988 EPX
294025 December 1988 EPX
317278 May 1989 EPX
319315 June 1989 EPX
9109614 July 1991 EPX
Other references
  • Pareti et al., J. Biol. Chem. 261(32):15310-15315 (1986) (Exhibit 4). Fujimura et al., J. Biol. Chem. 262(4):1734-1739 (1987) (Exhibit 5). Grossi et al., FASEB J. 2(8):2385-2395 (1988) (Exhibit 6). Mohri et al., Ca114:182561m (1990) (Exhibit 7). Mancuso et al., J. Biol. Chem. 264(33):19514-19527 (1989) (Exhibit 8). Carruthers et al., Biochemistry 28:8337-8346 (1989) (Exhibit 9). Fuster et al., Circulation Res. 51:587-593 (1982) (Exhibit 10). Kitigawa et al., Cancer res. 49:537-541 (1989) (Exhibit 11). Karpatkin et al., J. Clin. Invest. 81(4):1012-1019 (1988) (Exhibit 12). McBride et al., The New England Journal of Medicine 318(26):1734-1737 (1988) (Exhibit 13). Bellinger et al., P.N.A.S. 84:8100-8104 (1987) (Exhibit 14). Sadler, et al., PNAS USA 82: 6394-6398 (Oct. 1985). Girma, et al., Blood, 67: 1356-1366, (May 1986). Houdijk, et al. "Thrombosis and Haemostasis", 56:(3): 391-396 (Sep. 1986). Mohri, et al., J. Biological Chemistry, 264 (29): 17361-17367, (Oct. 1989). Sixma, et al., J. Clinical Investigations 74: 736-744, (Sep. 1984). Pietu, et al., Biochem. Biophys. Res. Comm. 164: 1339-1347 (Nov. 1989). Fujimura, et al., J. Biol. Chem. 261: 381-385 (Jan. 1986). Mohri, et al., J. Biol. Chem. 263: 17901-17904 (Dec. 1988). Sugimoto, et al., Abstract No. 2371 in Supplement to Circulation, 82: p. III-597 (Oct. 1990). Andrews, et al., Biochemistry, 28: 8326-8336, (1989). Sadler et al., Abstract No. 3950 in Federation Proceedings, vol. 44, No. 4, p. 1069 (Mar. 1985). Lynch et al., Cell, vol. 41, pp. 49-56 (May 1985). Ginsburg et al., Science, vol. 228, pp. 1401-1406 (Jun. 1985). Verweij et al., Nucleic Acids Research, vol. 13, No. 13, pp. 4699-4717 (Jul. 1985). Prior et al., Bio/Technology, vol. 10, pp. 66-73 (Jan. 1992). Fujimura et al., Abstract No. 1222 in Blood, vol. 66, p. 334a (Nov. 1985). Gralnick et al., Proc. Nalt. Acad. Sci., vol. 89, pp. 7880-7884 (1992). Wick et al., J. Clin. Invest., vol. 80, pp. 905-910 (1987). Peterson et al., Blood, vol. 69, pp. 625-628 (1987). Yammamoto et al., Thrumbosis Res., vol. 39, pp. 751-759 (1985). Harmon et al., Bio Chemistry, vol. 27, pp. 2151-2157 (1988). Pietu, et al, Production in E coli of a Biologically Active Subfragment of vWF corresponding to the platelet glycoprotein Ib, collagen & heparin, Biochemical and Biophysical Research Comm, 1989,. 164; 1339-1347.
Patent History
Patent number: 5837488
Type: Grant
Filed: Jun 5, 1995
Date of Patent: Nov 17, 1998
Assignee: Bio-Technology General Corp. (Iselin, NJ)
Inventors: Leonard Garfinkel (Rehovot), Tamar Richter (Nes Ziona)
Primary Examiner: Rebecca E. Prouty
Assistant Examiner: Tekchand Saidha
Attorney: John P. Cooper & Dunham LLP White
Application Number: 8/465,563
Classifications
Current U.S. Class: 435/691; 435/2523; 435/3201; 514/8; 514/12; 514/13; 514/17; 25 Or More Amino Acid Residues In Defined Sequence (530/324); 24 Amino Acid Residues In Defined Sequence (530/325); Proteins, I.e., More Than 100 Amino Acid Residues (530/350)
International Classification: C12P 2106; C12N 120; C12N 1500; A61K 3800;